Tenax Therapeutics (TENX) to Release Earnings on Tuesday

Tenax Therapeutics (NASDAQ:TENX) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Tenax Therapeutics to post earnings of ($0.48) per share for the quarter.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.34. On average, analysts expect Tenax Therapeutics to post $-1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Tenax Therapeutics Stock Down 4.3%

NASDAQ TENX opened at $5.57 on Monday. The stock has a market cap of $23.10 million, a P/E ratio of -1.05 and a beta of 1.92. The company’s 50-day simple moving average is $5.90 and its 200 day simple moving average is $5.88. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89.

Wall Street Analyst Weigh In

TENX has been the topic of a number of recent analyst reports. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. StockNews.com initiated coverage on shares of Tenax Therapeutics in a research report on Thursday. They issued a “sell” rating on the stock. Finally, Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.00.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.